【Native Speaker每日综合训练—38系列】【38-07】科技 Stem Cells

viennall

Speaker
Stem cells may be regarded as a quick fix for damaged heart tissue. The heart disease patients with stem cell therapy have stronger stickers for years to come than patients who are not treated with stem cell.

Speed
03'30 VC invested much less many to stem cells than other technology. Not only is the science too preliminary, but the business plans are to risky.
03'18 Stem cells have not been developed as a platform and too many companies are focusing on a single treatment for specific disease. The VC for stem cells in Europe may encounter obstacles, but have oppotunies in Australia and Sinapore.
02'09 Evan formed the Stem Cell Foundation to plug the gap between acadamic research and mid-stage clinical trials, which may attract more investment in stem cells.
01'54 It is unclear whether it will be possible to get a single regulatory approval to sell a stem cell therapy across the US. The market fragmentation makes stem cells very difficult model for big pharma.
00'49 VCs are dounted by the ethical and regulatory baggage surrounding stem cells.

obstacle
04'53

Main idea: The restrictions of new stell cell lines.
Structure:
The annoucement of the creation of stem cells lines from a cloned human embryo is a breakthrough in stem cell research.
But the research needs to be done under the US NIH regulatory lines.
The CIRM forbid paying the donors money for the eggs.
It is too difficult to receive the new stem cell lines within the rules of both NIH and CIRM.
Most labs will continue working with current stem cell lines due to the restrictions of NIH.
Some scientists think the restricions of NIH are overestimated.
CIRM is re-examing the rules. It does not likely alter the restrictions against the studies that pay cell donors. But other rules which will be overturn need much long time.